YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
- Conditions
- Hormone-Refractory Prostate CancerProstatic Neoplasms
- Registration Number
- NCT00048659
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Not specified
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (53)
Alaska Clinical Research Center, LLC
🇺🇸Anchorage, Alaska, United States
San Bernardino Urological Associates
🇺🇸San Bernardino, California, United States
Western Clinical Research, Inc.
🇺🇸Torrance, California, United States
Shands Hospital
🇺🇸Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center
🇺🇸Miami, Florida, United States
Georgia Urology,PA Research Institute
🇺🇸Atlanta, Georgia, United States
University of Chicago, Section of Hematology/Oncology
🇺🇸Chicago, Illinois, United States
University of Illinois, Department of Urology
🇺🇸Chicago, Illinois, United States
Michiana Hematology/Oncology
🇺🇸South Bend, Indiana, United States
The Urologic Institute of New Orleans
🇺🇸Gretna, Louisiana, United States
Scroll for more (43 remaining)Alaska Clinical Research Center, LLC🇺🇸Anchorage, Alaska, United States